| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2025 |
| Sales | 2,320 | 570 | 480 | 30 | 0 |
| Sales Growth | +307.02% | +18.75% | +1,500.00% | unch | unch |
| Net Income | -47,450 | -25,400 | -5,280 | -1,810 | 0 |
| Net Income Growth | -86.81% | -381.06% | -191.71% | unch | unch |
Avalanche Biot Cm ST (AAVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Avalanche Biotechnologies, Inc. is a biotechnology company. It engages in developing gene therapies for the treatment of ophthalmologic disorders. The Company's products under development includes AVA-101, AVA-201, AVA-311, AVA-322 and AVA-323. Using a next generation gene therapy platform, the Ocular BioFactory (TM), the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. Avalanche Biotechnologies, Inc. is headquartered in Menlo Park, California.